Skip to main content

CORRECTION article

Front. Immunol., 15 August 2023
Sec. Alloimmunity and Transplantation
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1272763

Expression of Concern: The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy

This article is a correction to:

  1. The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy

    1. Read original article
Frontiers Editorial Office* Frontiers Editorial Office*

    An Expression of concern on
    The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy

    by Portoles JM, Jimenez C, Janeiro D, Lopez-Oliva MO, Ortega-Carrion A, Blanquez D, Arribas L, Gomez C, Diez T, Pascual J and Portero I (2021). Front. Immunol. 11:618202. doi: 10.3389/fimmu.2020.618202

    With this notice, Frontiers states its awareness of concerns regarding the authorship of “The Immunobiogram, a Novel In Vitro Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy” published on 25 January 2021. Specifically, concerns have been raised that three individuals, Veronica Sánchez Rodríguez, Marianna di Scala, and Javier Dotor, have been excluded from the author list. An investigation was conducted in line with COPE guidelines involving the authors’ institution and the funding body, but unfortunately no conclusion could be reached.

    This Expression of Concern was approved by the Chief Editors of Frontiers in Immunology and the Chief Executive Editor of Frontiers. The authors do not agree to this Expression of Concern.

    Citation: Frontiers Editorial Office (2023) Expression of Concern: The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy. Front. Immunol. 14:1272763. doi: 10.3389/fimmu.2023.1272763

    Received: 04 August 2023; Accepted: 04 August 2023;
    Published: 15 August 2023.

    Approved by:

    Frontiers Editorial Office, Frontiers Media SA, Switzerland

    Copyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.